Kazia Therapeutics Limited

NasdaqCM KZIA

Kazia Therapeutics Limited Revenue for the year ending June 30, 2024: USD 1.54 M

Kazia Therapeutics Limited Revenue is USD 1.54 M for the year ending June 30, 2024, a 416,543.20% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Kazia Therapeutics Limited Revenue for the year ending June 30, 2023 was USD 369.35, a 2,040.77% change year over year.
Kazia Therapeutics Limited Revenue for the year ending June 30, 2022 was USD 17.25, a -100.00% change year over year.
Kazia Therapeutics Limited Revenue for the year ending June 30, 2021 was USD 11.38 M, a 1,554,203.10% change year over year.
Kazia Therapeutics Limited Revenue for the year ending June 30, 2020 was USD 732.41, a -33.35% change year over year.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

NasdaqCM: KZIA

Kazia Therapeutics Limited

CEO	Dr. John Edwin Friend II, M.D.
IPO Date	Jan. 6, 1999
Location	Australia
Headquarters	Three International Towers
Employees	9
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Key trends

Past 5 years